Automation of diagnostic genetic testing: Mutation detection by cyclic minisequencing

References

• Peltonen L. Molecular background of the Finnish disease heritage. Ann Med 1997;29:553–6.
   PubMed Web of Science ®Google Scholar
• Valkonen S, Hietala M, Savontaus ML, Aula P. Origin of Finnish mutations causing aspartylglucosaminuria. Hereditas 1999;131:191–5.
   PubMedGoogle Scholar
• Saarela J, Laine M, Oinonen C, von Schantz C, Jalanko A, Rouvinen J, Peltonen, L. Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations. Hum Mol Genet 2001;10:983–95.
   Google Scholar
• Hietala M, Gron K, Syvanen AC, Peltonen L, Aula P. Prospects of carrier screening of aspartylglucosaminuria in Finland. Eur J Hum Genet 1993;1:296–300.
   PubMedGoogle Scholar
• Peltonen L, Jalanko A, Varilo T. Molecular genetics of the Finnish disease heritage. Hum Mol Genet 1999;8: 1913–23.
   PubMed Web of Science ®Google Scholar
• Peltonen L, Pekkarinen P, Aaltonen J. Messages from an isolate: lessons from the Finnish gene pool. Biol Chem Hoppe Seyler 1995;376:697–704.
   PubMed Web of Science ®Google Scholar
• Sipila K, Aula P. Database for the mutations of the Finnish disease heritage. Hum Mutat 2002;19:16–22.
   Google Scholar
• Cohen J, Wilson A, Manzolillo K. Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics J 2013;4:378–88.
   Google Scholar
• Snyderman R. Personalized health care: From theory to practice. Biotechnol J 2012;7:973–9.
   Google Scholar
• Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res 2009; 154:277–87.
   PubMed Web of Science ®Google Scholar
• , SEARCH Collaborative GroupLink E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin- induced myopathy – a genomewide study. N Engl J Med 2008;359:789–99.
   PubMed Web of Science ®Google Scholar
• Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta 2005;1756:81–2.
   PubMed Web of Science ®Google Scholar
• Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008;40:600–8.
   PubMed Web of Science ®Google Scholar
• Amanuel B, Grieu F, Kular J, Millward M, Iacopetta B. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology 2012; 44:357–9.
   Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949–54.
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JB. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350–4.
   PubMed Web of Science ®Google Scholar
• Jalanko A, Kere J, Savilahti E, Schwartz M, Syvanen AC, Ranki M, Soderlund H. Screening for defined cystic fibrosis mutations by solid-phase minisequencing. Clin Chem 1992;38:39–43.
   Google Scholar
• Orpana AK. Fluorescence resonance energy transfer (FRET) using ssDNA binding fluorescent dye. Biomol Eng 2004; 21:45–50.
   Google Scholar
• Enattah NS, Sahi T, Savilahti E, Terwilliger JD, Peltonen L, Jarvela I. Identification of a variant associated with adult-type hypolactasia. Nat Genet 2002;30:233–7.
   PubMed Web of Science ®Google Scholar
• Ihalainen J, Siitari H, Laine S, Syvanen AC, Palotie A. Towards automatic detection of point mutations: use of scintillating microplates in solid-phase minisequencing. BioTechniques 1994;16:938–94.
   PubMedGoogle Scholar
• Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L, Campone M, Vallette FM, Gratas-Rabbia-Re C. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 2010;97:311–22.
   Google Scholar
• Nakagawachi T, Soejima H, Urano T, Zhao W, Higashimoto K, Satoh Y, Matsukura S, Kudo S, Kitajima Y, Harada H, Furukawa K, Matsuzaki H, Emi M, Nakabeppu Y, Miyazaki K, Sekiguchi M, Mukai T. Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 2003;22:8835–44.
   PubMedGoogle Scholar
• Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006;16: 101–10.
   PubMed Web of Science ®Google Scholar
• Coulthard S, Hogarth L. The thiopurines: an update. Invest New Drugs 2005;23:523–32.
   PubMed Web of Science ®Google Scholar
• Haglund S, Lindqvist M, Almer S, Peterson C, Taipalensuu J. Pyrosequencing of TPMT alleles in a general Swedish population and in patients with inflammatory bowel disease. Clin Chem 2004;50:288–95.
   PubMed Web of Science ®Google Scholar
• Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 2010;55: 582–9.
   PubMed Web of Science ®Google Scholar